A double-blinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in treatment of canine atopic dermatitis

Improvement of anemia in five dogs with nonregenerative anemia treated with allogeneic adipose-derived stem cells

“…Teshima et al., found that canine ADSCs produced extracellular vesicles, which inhibited the proliferation of Th1 and Th17 and enhanced Th2 and Treg cell proliferation. Although the therapeutic effects of ADSCs reported in dogs in immune-mediated diseases such as IBD ( Pérez-Merino, Usón-Casaús, Hermida-Prieto & Mariñas-Pardo, 2016 ) and CAD ( Kaur et al., 2021 ; Villatoro et al., 2018 ), no reports exist on the therapeutic effects of ADSCs for hematological diseases, and this is the first report of its kind.…”

“…MSCs are commonly derived from bone marrow or fat tissues and have been studied in veterinary medicine ( Voga, Adamic, Vengust & Majdic, 2020 ). They were previously thought to be a type of regenerative medicine, but in recent years, the possibility that they demonstrate immunomodulatory effects in dogs ( Cristóbal et al., 2021 ; Kaur et al.2021 ), as well as humans, have been raised, and their use for immunomodulation is being researched. In Japan, in 2015, allogeneic BM-derived stem cells were approved for use in the suppression of graft versus host disease (GVHD) after hematopoietic stem cell transplantation in humans.…”

“…In Japan, in 2015, allogeneic BM-derived stem cells were approved for use in the suppression of graft versus host disease (GVHD) after hematopoietic stem cell transplantation in humans. In dogs, canine adipose-derived stem cells (ADSCs) have been used to treat immune-mediated diseases, such as canine atopic dermatitis ( Kaur et al., 2021 ), inflammatory bowel disease (IBD) ( Cristóbal et al., 2021 ), and Keratoconjunctivitis sicca (KCS) ( Hermida-Prieto, García-Castro & Mariñas-Pardo, 2021 ) in addition to the regenerative purpose ( Olsson et al., 2021 ; Prządka et al., 2021 ). Furthermore, canine allogeneic ADSCs were approved by the Ministry of Agriculture, Forestry, and Fisheries for improvement of clinical signs associated with thoracolumbar disk herniation in dogs in 2021.…”

The effect of uterine-derived mesenchymal stromal cells for the treatment of canine atopic dermatitis: A pilot study

“…Clinical trials evaluating MSCs for cAD have yielded generally favorable results, with three out of four uncontrolled studies reporting positive clinical findings (12)(13)(14)(15). Most recently, Kaur et al conducted the first double-blind, placebo-controlled trial evaluating MSCs for cAD, in which affected dogs received adipose-derived, allogeneic MSCs via five SQ injections distributed across the body (16). Ninety days after the first treatment, owner-assessed Pruritus Visual Analog Scale (PVAS) scores were significantly lower in the treatment groups than with placebo.…”

“…All cAD studies to date have evaluated adipose-derived MSCs, requiring donors to undergo surgical excision of fat under general anesthesia (12)(13)(14)(15)(16). In contrast, uterine tissuederived MSCs (UMSCs) can be harvested from tissues removed during routine sterilization procedures, offering a virtually unlimited source of cells without additional surgery (17).…”